As part of Sleep Awareness Week^®, we welcome the contributions and perspectives of our sponsors. National Sleep Foundation (NSF) recognizes our Sleep Awareness Week 2023 Sponsors for their support of our sleep health mission and notes the information provided below does not necessarily reflect the views and opinions of NSF.

NLS Pharmaceutics is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs, such as narcolepsy and idiopathic hypersomnia. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates.

NLS understands that narcolepsy can affect every aspect of a person’s life, so we are acutely aware that those with narcolepsy and their families are often planning around it or basing their activities on the potential disruption that excessive daytime sleepiness or cataplexy can cause. We also understand that some people with narcolepsy find it very challenging to manage their symptoms and take multiple medications and that they may avoid some activities altogether.

We know that narcolepsy is a difficult disorder to manage and even with available treatments, most narcolepsy patients often require multiple medications several times throughout the day or night to treat their symptoms. NLS believes that people living with narcolepsy deserve options and access to appropriate treatment. The FDA’s The Voice of the Patient report concluded that there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy.

Keeping this in mind, NLS Pharmaceutics is developing a once-daily monotherapy that addresses both excessive daytime sleepiness and cataplexy symptoms. With positive Phase 2 results across primary and secondary endpoints, NLS plans to commence Phase 3 trials in the US this summer on once daily mazindol extended release.

Living with narcolepsy can be challenging for patients and families. NLS hopes to make it easier. For more information on this potential new treatment, please visit https://polaris.nlspharma.com/.

A Word from the National Sleep Foundation

The most obvious narcolepsy symptom is excessive daytime sleepiness (EDS) which refers to an inability to stay alert during normal daytime hours. You might feel persistently sleepy, no matter how much sleep you get at night. If you are practicing healthy sleep behaviors but still are experiencing these types of symptoms consider speaking to your healthcare provider. Learn more about narcolepsy here.